<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> increases the risk of <z:e sem="disease" ids="C0003972" disease_type="Disease or Syndrome" abbrv="ascvd">atherosclerotic cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Antioxidative properties of <z:chebi fb="6" ids="39025">high density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) are important for atheroprotection </plain></SENT>
<SENT sid="2" pm="."><plain>This study investigated whether the antioxidative functionality of <z:chebi fb="17" ids="39025">HDL</z:chebi> is altered in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and aimed to identify potential determinants of this parameter </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: In a cross-sectional study, we investigated 74 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and 75 control subjects </plain></SENT>
<SENT sid="4" pm="."><plain>Antioxidative properties of <z:chebi fb="17" ids="39025">HDL</z:chebi> were measured and expressed as either (i) <z:chebi fb="17" ids="39025">HDL</z:chebi> antioxidative capacity or (ii) <z:chebi fb="17" ids="39025">HDL</z:chebi> antioxidation index after multiplying <z:chebi fb="17" ids="39025">HDL</z:chebi> antioxidative capacity results with individual plasma <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> concentrations </plain></SENT>
<SENT sid="5" pm="."><plain>Lecithin:cholesterol acyltransferase (LCAT) and paraoxonase-1 (PON-1) activities were determined </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="17" ids="39025">HDL</z:chebi> antioxidative capacity was similar in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and controls, while the <z:chebi fb="17" ids="39025">HDL</z:chebi> antioxidation index was decreased in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> (P = 0.005) owing to lower plasma <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>LCAT activity was higher and PON-1 activity lower in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (each P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>In the combined subjects, <z:chebi fb="17" ids="39025">HDL</z:chebi> antioxidative capacity was inversely related to LCAT activity (P &lt; 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>The <z:chebi fb="17" ids="39025">HDL</z:chebi> antioxidation index correlated negatively with blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (P &lt; 0.001), HbA1c and LCAT activity (each P &lt; 0.01), and positively with PON-1 activity (P &lt; 0.01) </plain></SENT>
<SENT sid="10" pm="."><plain>Multiple linear regression analysis demonstrated that high LCAT activity was associated with both decreased <z:chebi fb="17" ids="39025">HDL</z:chebi> antioxidation capacity (P &lt; 0.05) and index (P &lt; 0.001) independent of <z:mp ids='MP_0002055'>diabetes</z:mp> status, glycaemic control and PON-1 </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Overall, the antioxidative functionality of <z:chebi fb="17" ids="39025">HDL</z:chebi> is impaired in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> mostly because of lower <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain><z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">Hyperglycaemia</z:e>, <z:mp ids='MP_0011599'>increased LCAT activity</z:mp> and lower PON-1 activity likely contribute to impaired antioxidative functionality of <z:chebi fb="17" ids="39025">HDL</z:chebi> </plain></SENT>
</text></document>